Foghorn Therapeutics Inc. (FHTX)

US — Healthcare Sector
Peers: CCCC  CYT  PRLD  RZLT  STTK  GLUE  KYMR  NRIX  MOLN  MNOV  ANEB  CSBR  PMVP  STOK  IPSC  EWTX  MLYS  CGEM 

Automate Your Wheel Strategy on FHTX

With Tiblio's Option Bot, you can configure your own wheel strategy including FHTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol FHTX
  • Rev/Share 0.374
  • Book/Share -0.981
  • PB -4.1592
  • Debt/Equity -0.5653
  • CurrentRatio 3.1611
  • ROIC -0.4957

 

  • MktCap 227424912.0
  • FreeCF/Share -1.5253
  • PFCF -2.3724
  • PE -3.1878
  • Debt/Assets 0.1347
  • DivYield 0
  • ROE 2.148

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation FHTX Citizens JMP -- Mkt Outperform -- $9 April 23, 2025
Initiation FHTX B. Riley Securities -- Buy -- $10 Jan. 30, 2025
Initiation FHTX Jefferies -- Buy -- $18 Sept. 3, 2024
Initiation FHTX Evercore ISI -- Outperform -- $20 Aug. 19, 2024

News

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
FHTX
Published: May 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Read More
image for news Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
FHTX
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Neutral

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.

Read More
image for news Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
FHTX
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Read More
image for news Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

About Foghorn Therapeutics Inc. (FHTX)

  • IPO Date 2020-10-23
  • Website https://foghorntx.com
  • Industry Biotechnology
  • CEO Mr. Adrian H. B. Gottschalk
  • Employees 112

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.